Advanced in RASopathies

Dr. Brigitte C. Widemann

Pediatric Hematology Oncology
8906 Bradmoor Dr, 
Bethesda, MD 
 (919.8 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in RASopathies
8906 Bradmoor Dr, 
Bethesda, MD 
 (919.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Brigitte Widemann is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Widemann and is rated as an Advanced provider by MediFind in the treatment of RASopathies. Her top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Adult Soft Tissue Sarcoma, and Thyroidectomy.

Her clinical research consists of co-authoring 204 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of RASopathies.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MD
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

8906 Bradmoor Dr, Bethesda, MD 20817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Natural History Study of Children and Adults With Chordoma
Natural History Study of Children and Adults With Chordoma
Enrollment Status: Recruiting
Publish Date: December 02, 2024
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Drug
Study Drug: Selumetinib
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
Enrollment Status: Completed
Publish Date: December 06, 2023
Intervention Type: Drug, Other
Study Drugs: Selumetinib, Selumetinib Sulfate
Study Phase: Phase 2
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 29, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

203 Total Publications

Advances in pediatric oncology through collaborations.
Advances in pediatric oncology through collaborations.
Journal: Current opinion in pediatrics
Published: December 19, 2024
Similar Doctors
Experienced in RASopathies
Dr. Susan L. Whiteway
Pediatric Hematology Oncology
Experienced in RASopathies
Dr. Susan L. Whiteway
Pediatric Hematology Oncology
8901 Wisconsin Ave, 
Bethesda, MD 
 (1.5 mi)
301-400-1663
Languages Spoken:
English

Susan Whiteway is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Whiteway and is rated as an Experienced provider by MediFind in the treatment of RASopathies. Her top areas of expertise are Chromosome 7p Deletion, RASopathies, Glioma, and Adult Soft Tissue Sarcoma.

Experienced in RASopathies
Dr. Sharon A. Savage
Pediatric Hematology Oncology
Experienced in RASopathies
Dr. Sharon A. Savage
Pediatric Hematology Oncology
10 Center Drive, National Institutes Of Health Clinical Center, 
Bethesda, MD 
 (0.9 mi)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Savage and is rated as an Elite provider by MediFind in the treatment of RASopathies. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile